3 June 2021 - Thankfully, version 3 clearly notes what has been revised.

Version 3 of the agenda for the July 2021 PBAC meeting was published on 1 June 2021. There are two changes:

• The addition of a submission for enzalutamide (Xtandi) and abiraterone acetate (Zytiga) - prostate cancer
• The withdrawal of a submission for nivolumab (Opdivo) - gastro-oesophageal junction cancer or oesophageal adenocarcinoma

Alas, consumers won't be able to comment on the submission for the two medicines for patients with prostate cancer as the closing date for comments was 26 May 2021.

Read PBAC agenda